ASCO Announces Its Own Trial

Article

June 1, 2015.

The American Society of Clinical Oncology (ASCO) will run a trial of its enrolling patients with advanced cancers but a dearth of standard treatment options. The trial will offer molecularly-targeted cancer drugs contributed free of charge by participating pharma companies.

The Targeted Agent and Profiling Utilization Registry (TAPUR) study will give “real-world” data on best uses of these drugs outside of approved indications.

ASCO petitioned several companies to sign on. Five major companies, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, and Pfizer, so far, have agreed to participate by signing memoranda of understanding.

See the press release here.

Recent Videos
Ted Sweetser
Ted Sweetser
Ted Sweetser
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Jennifer Kyle, Condor